Oncology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Braftovi"

Over 60% of patients with stage IV melanoma may develop brain metastases, resulting in a significantly increased morbidity and poor overall prognosis. Clinical data for melanoma brain metastases ( M ...

The triplet combination of the BRAF inhibitor, Encorafenib ( Braftovi ), MEK inhibitor, Binimetinib ( Mektovi ), and EGFR inhibitor, Cetuximab ( Erbitux ), not only has significantly improved overall ...

Treatment of patients with BRAF V600–mutant melanoma includes BRAF/MEK-inhibitor combinations based on demonstrated benefits on progression-free survival ( PFS ) and overall survival ( OS ). To bett ...